ArticleJournal of translational autoimmunity2025
MiR-122-5p modulates ferroptosis via SLC7A11: A potential therapeutic target in autoimmune hepatitis.
Article in Journal of translational autoimmunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis regulatory networks and precision interventions in autoimmune hepatitis: comparison with cholestatic diseases.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & aims: Autoimmune hepatitis (AIH) is a relatively rare cause of liver disease with a poor prognosis without intervention. Ferroptosis, a classical form of cell death, plays a crucial role in various diseases, but its role in AIH remains unclear. Therefore, we investigated the role of ferroptosis in AIH and its mechanism. Methods: Here, we performed extensive bioinformatic analyses using online public database and tools, including Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis. Ferroptosis-related assay kits, quantitative real-time polymerase chain reaction, and Western blot analysis were used to validate the results by using clinical tissues and cell samples. Results: We obtained 449 differentially expressed microRNAs (DEmiRNAs) between the control and AIH groups. Among these, hsa-miR-122-5p and hsa-miR-143-3p were screened out as potential key miRNAs by evaluating their diagnostic value, expression levels, and number of target genes. Enrichment analysis revealed a significant association between hsa-miR-122-5p and ferroptosis-related pathways. It was confirmed by in vitro assays that hsa-miR-122-5p inhibited the SLC7A11 expression, thereby promoting ferroptosis in AIH. Conclusions: To summarize, our study demonstrated that hsa-miR-122-5p, as a potential therapeutic target, promotes ferroptosis by inhibiting the expression of SLC7A11, which provides new insights into the pathogenesis of AIH and paves the way for innovative treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.